Benitec Biopharma Inc
NASDAQ:BNTC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.7
16.79
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Benitec Biopharma Inc
Benitec Biopharma, Inc. is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The company is headquartered in Hayward, California and currently employs 14 full-time employees. The company went IPO on 2012-07-11. The firm is focused on developing a therapeutic technology platform that combines ribonucleic acid (RNA) interference with gene therapy for the goal of silencing disease-causing genes from a single administration. The firm's technology, deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi), is used to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Its pipeline includes BB-301, and BB-103. The firm's lead product candidate, BB-301, is used for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). Its BB-103 pipeline product is being developed for the treatment of chronic hepatitis B Virus infection.
Benitec Biopharma, Inc. is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The company is headquartered in Hayward, California and currently employs 14 full-time employees. The company went IPO on 2012-07-11. The firm is focused on developing a therapeutic technology platform that combines ribonucleic acid (RNA) interference with gene therapy for the goal of silencing disease-causing genes from a single administration. The firm's technology, deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi), is used to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Its pipeline includes BB-301, and BB-103. The firm's lead product candidate, BB-301, is used for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). Its BB-103 pipeline product is being developed for the treatment of chronic hepatitis B Virus infection.
Program Progress: Benitec advanced its oncology and OPMD gene therapy programs, with a Phase 2 oncology study now active and OPMD clinical entry targeted for early 2019.
Capital Raised: The company raised $8.8 million through an entitlement offer and placement, with strong support from major shareholders.
Financials: Benitec reported a net loss of $8.6 million for Q3 2018, wider than the $3.1 million loss in Q3 2017, mainly due to reduced R&D grant income.
Cash Position: Cash on hand at the end of March 2018 was $10.5 million, down $6.8 million from June 2017.
Regulatory Momentum: Positive feedback from regulators in key countries supports the clinical advancement of BB-301 for OPMD.
Manufacturing Advances: Significant progress in scalable manufacturing for gene therapy products, with clinical-grade material production ramping up.
